Biden Administration Faces Opposition over Proposed Menthol Ban

Regulations by 2FIRSTS.ai

Nov.20.2023

Biden Administration Faces Opposition over Proposed Menthol Ban

Biden administration faces bipartisan opposition as it considers a ban on menthol cigarettes, with concerns about economic impact and racial disparities.

According to a report in The Washington Observer on November 19, the Biden administration is facing opposition from both parties over its decision on the proposed ban on menthol cigarettes. Critics argue that this move will have a negative impact on the economy and disproportionately affect communities of color.

The decision on whether to implement a ban on menthol cigarettes and flavored cigars is expected to be released as early as this week, following the first proposal made by the Food and Drug Administration (FDA) in spring 2021.

Legislators and advocacy groups have criticized the proposal, arguing that it would lead to an increase in illegal sales and inconsistent enforcement.

References:

[1] Biden faces bipartisan opposition over looming menthol cigarette ban

Also Read:

[1] Biden Opposes Bill to Limit FDA's Power

#Menthol cigarettes

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn

Notice

1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

Copyright

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

AI Assistance Disclaimer

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Following Japan debut, IQOS ILUMA i “Seletti Edition” limited series launches in South Korea.

Philip Morris International (PMI) Korea announced a collaboration with Italian design brand Seletti to launch the IQOS ILUMA i limited “Seletti Edition.” Pre-sales begin on the 29th at IQOS.com for IQOS Club Gold and Platinum members, with sales from the 30th via the website and nine IQOS-owned stores nationwide. PMI previously said the series would debut in Japan first before rolling out to 13 global travel-retail markets.

Oct.29 by 2FIRSTS.ai

Co-op Faces Backlash Over Vape Promotion Strategy Post-Cyberattack

The Guardian reports that UK retailer Co-op is ramping up vape promotions to recover sales lost after an April cyberattack. Internal documents cite a £1M weekly sales gap and 100,000 fewer transactions. Staff say the move contradicts Co-op’s “ethical retail” image, as the government prepares to ban vape ads under the Tobacco and Vapes Bill.

Oct.28 by 2FIRSTS.ai

U.S. FDA Includes Cytisinicline for Vaping Addiction in National Priority Voucher Program, Shortens Review to 1–2 Months

The U.S. Food and Drug Administration (FDA) has added Cytisinicline, a plant-based therapy developed by Achieve Life Sciences for nicotine vaping addiction, to its new National Priority Voucher (CNPV) program. The initiative shortens drug review timelines from 10–12 months to just 1–2 months, expediting approval for treatments that address major public health needs.

Oct.20 by 2FIRSTS.ai

Product | Differences in Configuration and Indicator Methods: Three UWELL G5 Series Devices Launch on U.S. and U.K. Channels

UWELL has launched three models in its Caliburn G5 Lite series across U.S. and U.K. channels, using indicator lights or breathing lights to display device status. Compared with the earlier G4 series, the new G5 Lite lineup continues a screenless design and increases battery capacity to 1,600mAh. The three devices also share the same core specifications, including e-liquid capacity, maximum power output, and pod compatibility.